Safety and efficacy of dexamethasone intravitreal implant for treatment of macular edema secondary to retinal vein occlusion in Chinese patients: randomized, sham-controlled, multicenter study

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 256, Issue 1, 2018, Pages 59-69

  Li, Xiaoxin ^a,b   Wang, Ningli ^c   Liang, Xiaoling ^d   Xu, Gezhi ^e   Li, Xiao Yan ^f   Jiao, Jenny ^f   Lou, Jean ^f   Hashad, Yehia ^f  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d SUN YAT SEN UNIVERSITY   (China)

^e EYE AND ENT HOSPITAL OF FUDAN UNIVERSITY   (China)

^f ALLERGAN INC   (United States)

Author keywords

Corticosteroid; Drug delivery system; Intravitreal injection; Macular edema; Randomized controlled trial; Retinal vein occlusion

Indexed keywords

DEXAMETHASONE; GLUCOCORTICOID;

ADULT; ADVERSE DRUG REACTION; ARTICLE; BEST CORRECTED VISUAL ACUITY; BRANCH RETINAL VEIN OCCLUSION; CATARACT; CENTRAL RETINA VEIN OCCLUSION; CENTRAL RETINAL THICKNESS; CHEMOSIS; CHINESE; CHRONIC CHOLECYSTITIS; CLINICAL EVALUATION; COMPARATIVE STUDY; CONJUNCTIVAL HEMORRHAGE; CONJUNCTIVAL HYPEREMIA; CONTROLLED STUDY; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EYE PAIN; FEMALE; HEADACHE; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MACULAR EDEMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SHAM PROCEDURE; SIDE EFFECT; TIME TO TREATMENT; TOPICAL TREATMENT; TREATMENT DURATION; VISUAL ACUITY; VITREOUS HEMORRHAGE; AGED; CHINA; CLINICAL TRIAL; COMPLICATION; DRUG IMPLANT; FOLLOW UP; INCIDENCE; INTRAVITREAL DRUG ADMINISTRATION; MIDDLE AGED; PATHOLOGY; RETINA; RETINA VEIN OCCLUSION; TIME FACTOR; TREATMENT OUTCOME; VITREOUS BODY; YOUNG ADULT;

ADULT; AGED; CHINA; DEXAMETHASONE; DOUBLE-BLIND METHOD; DRUG IMPLANTS; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; INCIDENCE; INTRAOCULAR PRESSURE; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; RETINA; RETINAL VEIN OCCLUSION; TIME FACTORS; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VISUAL ACUITY; VITREOUS BODY; YOUNG ADULT;

EID: 85033388130     PISSN: 0721832X     EISSN: 1435702X     Source Type: Journal    
DOI: 10.1007/s00417-017-3831-6     Document Type: Article

References (23)

1. Jonas JB, Xu L, Wang YX (2009) The Beijing eye study. Acta Ophthalmol 87:247–261. https://doi.org/10.1111/j.1755-3768.2008.01385.x
2. Rehak M, Wiedemann P (2010) Retinal vein thrombosis: Pathogenesis and management. J Thromb Haemost 8:1886–1894. https://doi.org/10.1111/j.1538-7836.2010.03909.x
3. Fujihara-Mino A, Mitamura Y, Inomoto N, Sano H, Akaiwa K, Semba K (2016) Optical coherence tomography parameters predictive of visual outcome after anti-VEGF therapy for retinal vein occlusion. Clin Ophthalmol 10:1305–1313. https://doi.org/10.2147/OPTH.S110793
4. Deobhakta A, Chang LK (2013) Inflammation in retinal vein occlusion. Int J Inflam 2013:438412. https://doi.org/10.1155/2013/438412
5. Jonas JB (2005) Intravitreal triamcinolone acetonide for treatment of intraocular oedematous and neovascular diseases. Acta Ophthalmol Scand 83:645–663
6. Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jiao J, Li XY, Whitcup SM, Ozurdex GENEVA Study Group (2011) Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology 118:2453–2460. https://doi.org/10.1016/j.ophtha.2011.05.014
7. Robinson MR, Whitcup SM (2012) Pharmacologic and clinical profile of dexamethasone intravitreal implant. Expert Rev Clin Pharmacol 5:629–647. https://doi.org/10.1586/ecp.12.55
8. Haller JA, Dugel P, Weinberg DV, Chou C, Whitcup SM (2009) Evaluation of the safety and performance of an applicator for a novel intravitreal dexamethasone drug delivery system for the treatment of macular edema. Retina 29:46–51. https://doi.org/10.1097/IAE.0b013e318188c814
9. Chang-Lin JE, Attar M, Acheampong AA, Robinson MR, Whitcup SM, Kuppermann BD, Welty D (2011) Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci 52:80–86. https://doi.org/10.1167/iovs.10-5285
10. Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jacques ML, Jiao J, Li XY, Whitcup SM, OZURDEX GENEVA Study Group (2010) Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 117:1134–1146.e3. https://doi.org/10.1016/j.ophtha.2010.03.032
11. Kuppermann BD, Haller JA, Bandello F, Loewenstein A, Jiao J, Li XY, Whitcup SM (2014) Onset and duration of visual acuity improvement after dexamethasone intravitreal implant in eyes with macular edema due to retinal vein occlusion. Retina 34:1743–1749. https://doi.org/10.1097/IAE.0000000000000167
12. Cheng JW, Cheng SW, Ma XY, Cai JP, Li Y, Wei RL (2013) The prevalence of primary glaucoma in mainland China: A systematic review and meta-analysis. J Glaucoma 22:301–306. https://doi.org/10.1097/IJG.0b013e31824083ca
13. Early Treatment Diabetic Retinopathy Study Research Group (1985) Photocoagulation for diabetic macular edema. Early treatment diabetic retinopathy study report number 1. Arch Ophthalmol 103:1796–1806
14. Chew EY, Kim J, Sperduto RD, Datiles MB 3rd, Coleman HR, Thompson DJ, Milton RC, Clayton JA, Hubbard LD, Danis RP, Ferris FL 3rd (2010) Evaluation of the age-related eye disease study clinical lens grading system. AREDS report no. 31. Ophthalmology 117:2112–2119.e3. https://doi.org/10.1016/j.ophtha.2010.02.033
15. Yeh WS, Haller JA, Lanzetta P, Kuppermann BD, Wong TY, Mitchell P, Whitcup SM, Kowalski JW (2012) Effect of the duration of macular edema on clinical outcomes in retinal vein occlusion treated with dexamethasone intravitreal implant. Ophthalmology 119:1190–1198. https://doi.org/10.1016/j.ophtha.2011.12.028
16. Jaissle GB, Szurman P, Feltgen N, Spitzer B, Pielen A, Rehak M, Spital G, Heimann H, Meyer CH, Retinal Vein Occlusion Study Group (2011) Predictive factors for functional improvement after intravitreal bevacizumab therapy for macular edema due to branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 249:183–192. https://doi.org/10.1007/s00417-010-1470-2
17. Larsen M, Waldstein SM, Boscia F, Gerding H, Monés J, Tadayoni R, Priglinger S, Wenzel A, Barnes E, Pilz S, Stubbings W, Pearce I, CRYSTAL Study Group (2016) Individualized ranibizumab regimen driven by stabilization criteria for central retinal vein occlusion: Twelve-month results of the CRYSTAL study. Ophthalmology 123:1101–1111. https://doi.org/10.1016/j.ophtha.2016.01.011
18. Augustin AJ, Holz FG, Haritoglou C, Mayer WJ, Bopp S, Scheuerle AF, Maier M, Sekundo W, Sandner D, Shirlaw A, Hattenbach LO (2015) Retrospective, observational study in patients receiving a dexamethasone intravitreal implant 0.7 mg for macular oedema secondary to retinal vein occlusion. Ophthalmologica 233:18–26. https://doi.org/10.1159/000368840
19. Singer MA, Capone A Jr, Dugel PU, Dreyer RF, Dodwell DG, Roth DB, Shi R, Walt JG, Scott LC, Hollander DA, SHASTA Study Group (2015) Two or more dexamethasone intravitreal implants as monotherapy or in combination therapy for macular edema in retinal vein occlusion: Subgroup analysis of a retrospective chart review study. BMC Ophthalmol 15:33. https://doi.org/10.1186/s12886-015-0018-y
20. Querques L, Querques G, Lattanzio R, Gigante SR, Del Turco C, Corradetti G, Cascavilla ML, Bandello F (2013) Repeated intravitreal dexamethasone implant (Ozurdex®) for retinal vein occlusion. Ophthalmologica 229:21–25. https://doi.org/10.1159/000342160
21. Eter N, Mohr A, Wachtlin J, Feltgen N, Shirlaw A, Leaback R, German Ozurdex in RVO Real World Study Group (2016) Dexamethasone intravitreal implant in retinal vein occlusion: Real-life data from a prospective, multicenter clinical trial. Graefes Arch Clin Exp Ophthalmol 255:77–87. https://doi.org/10.1007/s00417-016-3431-x
22. Maturi RK, Pollack A, Uy HS, Varano M, Gomes AM, Li XY, Cui H, Lou J, Hashad Y, Whitcup SM, Ozurdex MEAD Study Group (2016) Intraocular pressure in patients with diabetic macular edema treated with dexamethasone intravitreal implant in the 3-year MEAD study. Retina 36:1143–1152. https://doi.org/10.1097/IAE.0000000000001004
23. Reid GA, Sahota DS, Sarhan M (2015) Observed complications from dexamethasone intravitreal implant for the treatment of macular edema in retinal vein occlusion over 3 treatment rounds. Retina 35:1647–1655. https://doi.org/10.1097/IAE.0000000000000524